Midterm outcomes of off-the-shelf multibranched versus physician-modified endografts for endovascular repair of complex and thoracoabdominal aortic aneurysms: A systematic review and meta-analysis.

IF 3.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
Kenneth Han, Hyejin Mo, Shreya Guha, Miju Bae, Carrie Tackett, Sukgu M Han
{"title":"Midterm outcomes of off-the-shelf multibranched versus physician-modified endografts for endovascular repair of complex and thoracoabdominal aortic aneurysms: A systematic review and meta-analysis.","authors":"Kenneth Han, Hyejin Mo, Shreya Guha, Miju Bae, Carrie Tackett, Sukgu M Han","doi":"10.1016/j.jvs.2026.03.616","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Custom-manufactured fenestrated-branched endovascular aortic repair devices have demonstrated excellent outcomes for elective repair of complex abdominal (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). However, for symptomatic or ruptured aneurysms, the manufacturing and shipping time render this option impractical for urgent or emergent repair. To address this clinical need, alternative technologies have been developed, including physician-modified endografts (PMEGs) and off-the-shelf multibranched devices (OTSDs). In this systematic review and meta-analysis, we compare midterm outcomes between OTSDs and PMEGs.</p><p><strong>Design/method: </strong>A systematic search was conducted using the MEDLINE, Embase, Scopus, and ClinicalTrials.gov databases through January 1, 2025. Studies with 10 or more patients reporting 1- or 2-year mortality or reintervention after PMEG or OTSD repair of CAAAs or TAAAs were included. Primary outcomes included midterm reintervention and mortality. Secondary outcomes included 30-day mortality, spinal cord ischemia (SCI), and technical success. Subgroup analyses by presentation and aneurysm extent were also performed.</p><p><strong>Results: </strong>Eighteen studies (11 PMEG, 7 OTSD), including 994 patients (538 PMEGs, 456 OTSDs), were included in the review. One-year reintervention was 11% for PMEG and 12% for OTSD (P = .966), and 2-year reintervention was 15% for PMEG and 13% for OTSD (P = .820). One-year mortality was 9% for PMEG and 8% for OTSD (P = .714), and 2-year mortality was 11% for PMEG and 12% for OTSD (P = .758). Technical success was slightly higher with OTSD (98% vs 96%, P = .03), and SCI occurred more frequently with OTSD (6% vs 0%, P < .0001). Thirty-day mortality was 1% for PMEG and 2% for OTSD (P = .836). Subgroup analyses by presentation and aneurysm extent revealed no differences in primary outcomes.</p><p><strong>Conclusions: </strong>PMEGs and OTSDs demonstrate acceptable midterm outcomes. However, interpretation of comparative results is limited by substantial differences in aneurysm extent, symptomatic or ruptured presentation, and follow-up duration between the cohorts. Both remain viable strategies, with device selection guided by individual anatomy, urgency, and institutional expertise.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvs.2026.03.616","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Custom-manufactured fenestrated-branched endovascular aortic repair devices have demonstrated excellent outcomes for elective repair of complex abdominal (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). However, for symptomatic or ruptured aneurysms, the manufacturing and shipping time render this option impractical for urgent or emergent repair. To address this clinical need, alternative technologies have been developed, including physician-modified endografts (PMEGs) and off-the-shelf multibranched devices (OTSDs). In this systematic review and meta-analysis, we compare midterm outcomes between OTSDs and PMEGs.

Design/method: A systematic search was conducted using the MEDLINE, Embase, Scopus, and ClinicalTrials.gov databases through January 1, 2025. Studies with 10 or more patients reporting 1- or 2-year mortality or reintervention after PMEG or OTSD repair of CAAAs or TAAAs were included. Primary outcomes included midterm reintervention and mortality. Secondary outcomes included 30-day mortality, spinal cord ischemia (SCI), and technical success. Subgroup analyses by presentation and aneurysm extent were also performed.

Results: Eighteen studies (11 PMEG, 7 OTSD), including 994 patients (538 PMEGs, 456 OTSDs), were included in the review. One-year reintervention was 11% for PMEG and 12% for OTSD (P = .966), and 2-year reintervention was 15% for PMEG and 13% for OTSD (P = .820). One-year mortality was 9% for PMEG and 8% for OTSD (P = .714), and 2-year mortality was 11% for PMEG and 12% for OTSD (P = .758). Technical success was slightly higher with OTSD (98% vs 96%, P = .03), and SCI occurred more frequently with OTSD (6% vs 0%, P < .0001). Thirty-day mortality was 1% for PMEG and 2% for OTSD (P = .836). Subgroup analyses by presentation and aneurysm extent revealed no differences in primary outcomes.

Conclusions: PMEGs and OTSDs demonstrate acceptable midterm outcomes. However, interpretation of comparative results is limited by substantial differences in aneurysm extent, symptomatic or ruptured presentation, and follow-up duration between the cohorts. Both remain viable strategies, with device selection guided by individual anatomy, urgency, and institutional expertise.

现成的多分支和医生改良的血管内移植用于复杂胸腹主动脉瘤血管内修复的中期结果:系统回顾和荟萃分析
背景:定制制造(CMD) FBEVAR装置在复杂腹腔(CAAA)和胸腹主动脉瘤(TAAA)的选择性修复中显示出良好的效果。然而,对于有症状或破裂的动脉瘤,制造和运输时间使得这种选择不适合紧急或紧急修复。为了满足这一临床需求,已经开发了替代技术,包括医生修改的内移植物(PMEG)和现成的多分支设备(OTSD)。在本系统综述和荟萃分析中,我们比较了OTSD和PMEG的中期结果。设计/方法:使用MEDLINE、Embase、Scopus和ClinicalTrials.gov数据库进行系统检索,截止日期为2025年1月1日。研究纳入了10例或更多患者报告PMEG或OTSD修复CAAA或TAAA后1年或2年死亡率或再干预的研究。主要结局包括中期再干预和死亡率。次要结局包括30天死亡率、脊髓缺血(SCI)和技术成功。根据表现和动脉瘤范围进行亚组分析。结果:纳入18项研究(11项PMEG, 7项OTSD), 994例患者(538例PMEG, 456例OTSD)。PMEG组1年再干预率为11%,OTSD组为12% (P=.966), PMEG组2年再干预率为15%,OTSD组为13% (P=.820)。PMEG 1年死亡率为9%,OTSD为8% (P=.714), PMEG 2年死亡率为11%,OTSD为12% (P=.758)。OTSD的技术成功率略高(98%对96%,P=.03),而OTSD的SCI发生率更高(6%对0%,P)。结论:PMEG和OTSD表现出可接受的中期结果。然而,对比较结果的解释受到队列之间动脉瘤范围、症状或破裂表现以及随访时间的实质性差异的限制。这两种方法都是可行的,设备的选择要根据个人的解剖情况、急迫性和机构的专业知识进行指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.70
自引率
18.60%
发文量
1469
审稿时长
54 days
期刊介绍: Journal of Vascular Surgery ® aims to be the premier international journal of medical, endovascular and surgical care of vascular diseases. It is dedicated to the science and art of vascular surgery and aims to improve the management of patients with vascular diseases by publishing relevant papers that report important medical advances, test new hypotheses, and address current controversies. To acheive this goal, the Journal will publish original clinical and laboratory studies, and reports and papers that comment on the social, economic, ethical, legal, and political factors, which relate to these aims. As the official publication of The Society for Vascular Surgery, the Journal will publish, after peer review, selected papers presented at the annual meeting of this organization and affiliated vascular societies, as well as original articles from members and non-members.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书